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Transforming growth 
factor β-activated kinase 1 
transcriptionally suppresses 
hepatitis B virus replication
Jinke Pang1,2,*, Geng Zhang1,*, Yong Lin2, Zhanglian Xie1, Hongyan Liu1,3, Libo Tang1, 
Mengji Lu2, Ran Yan4, Haitao Guo4, Jian  Sun1, Jinlin Hou1 & Xiaoyong Zhang1
Hepatitis B Virus (HBV) replication in hepatocytes is restricted by the host innate immune system and 
related intracellular signaling pathways. Transforming growth factor β-activated kinase 1 (TAK1) is a 
key mediator of toll-like receptors and pro-inflammatory cytokine signaling pathways. Here, we report 
that silencing or inhibition of endogenous TAK1 in hepatoma cell lines leads to an upregulation of HBV 
replication, transcription, and antigen expression. In contrast, overexpression of TAK1 significantly 
suppresses HBV replication, while an enzymatically inactive form of TAK1 exerts no effect. By screening 
TAK1-associated signaling pathways with inhibitors and siRNAs, we found that the MAPK-JNK pathway 
was involved in TAK1-mediated HBV suppression. Moreover, TAK1 knockdown or JNK pathway 
inhibition induced the expression of farnesoid X receptor α, a transcription factor that upregulates 
HBV transcription. Finally, ectopic expression of TAK1 in a HBV hydrodynamic injection mouse model 
resulted in lower levels of HBV DNA and antigens in both liver and serum. In conclusion, our data 
suggest that TAK1 inhibits HBV primarily at viral transcription level through activation of MAPK-JNK 
pathway, thus TAK1 represents an intrinsic host restriction factor for HBV replication in hepatocytes.
Hepatitis B virus (HBV) infection is a major health concern worldwide, causing a wide spectrum of liver diseases 
in more than 240 million people. It is estimated that one million deaths occur each year due to HBV-related 
severe liver diseases, including liver cirrhosis, liver failure, and hepatocellular carcinoma (HCC)1. Currently, only 
nucleotide analogues and interferons (IFNs) are approved for the treatment of chronic hepatitis B (CHB) patients. 
However, it is difficult to achieve immune control or HBV clearance in the majority of patients using available 
antiviral agents2. It is generally accepted that host immune responses determine the clearance or persistence of 
HBV infection3.
HBV is a hepatotropic, enveloped virus of the Hepadnaviridae family with a partial double-stranded relaxed 
circular DNA genome. After infection of hepatocytes via the sodium taurocholate cotransporting polypeptide 
(NTCP) receptor4, the uncoated viral genome is transported to the nucleus and converted into an episomal 
covalently closed circular (ccc) DNA form, which serves as the template for synthesis of viral transcripts. The 
longest (3.5 -kb) mRNA includes two species, precore mRNA encodes the precore (HBeAg), and pregenomic 
RNA (pgRNA) translates core (HBcAg) and polymerase proteins. The pgRNA also serves as reverse transcrip-
tion template after encapsidation into the HBcAg-derived nucleocapsid. Other transcripts including the 2.4 and 
2.1 -kb viral mRNAs encode the large, middle, and small surface proteins (HBsAg), and the 0.7 -kb viral mRNA 
encodes the non-structural HBV X protein. The transcription of these viral mRNAs in hepatocytes is intensively 
controlled by the core, S1, S2, and X promoters and two enhancer regions (EnhI and EnhII)5. Many liver enriched 
transcription factors, such as hepatocyte nuclear factor 4α (HNF-4α ) and farnesoid X receptor α (FXRα ), are able 
to target the promoter and enhancer regions to regulate HBV replication and transcription6.
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Efficient control of HBV infection requires coordinated action of both innate and adaptive immunity. Central 
to these antiviral responses is the secretion of IFNs or inflammatory cytokines, which promote specific T cell 
responses or target HBV-infected hepatocytes directly to limit virus infection7. HBV specific CD8+ T cells secrete 
IFN-γ and tumor necrosis factor-α (TNF-α ) to clear HBV infection through a noncytopathic mechanism8. In 
primary human hepatocytes and human hepatoma cells, IFN-γ and TNF-α are able to inhibit HBV replication by 
inducing deamination and subsequent decay of cccDNA9. Moreover, toll-like receptor (TLR) ligands, as well as 
other cytokines (interleukin IL-1β , IL-6 and transforming growth factor-β [TGF-β ], etc.), activate multiple down-
stream signaling pathways to suppress HBV replication in hepatoma cells through the transcriptional regulation 
of HBV RNA10–13. These studies suggest that TLRs or cytokines, which relate to innate and adaptive immunity, 
play an active role in the intracellular control of HBV replication and gene expression in hepatocytes.
TGF-β activated kinase 1 (TAK1, also known as MAP3K7) was discovered in 1995 as a serine/threonine kinase 
of the mitogen-activated protein kinase kinase kinase (MAPKKK) family14. It is a key adaptor protein in the sig-
naling of TLRs and various cytokines, such as TNF-α , IL-1β and TGF-β 15. Once activated by these cytokines or 
TLR ligands, TAK1 can be phosphorylated and polyubiquitinated by TNF-receptor-associated factors and in 
turn activates downstream pathways, including p38, c-jun N-terminal kinase (JNK) and Iκ B kinase. p38 and 
JNK of MAPK pathway control the transcription factor activator protein-1 (AP-1), while nuclear factor-kappa B 
(NF-κ B) is activated by Iκ B kinase. In general, TAK1 regulates NF-κ B and AP-1 activation in a cell-specific and 
receptor-specific manner16. Several reports by Seki’s group have addressed the function of TAK1 in liver devel-
opment and proinflammatory signaling in hepatocytes. They found that hepatocyte-specific deletion of TAK1 in 
mice results in spontaneous hepatocyte death, inflammation, fibrosis, and carcinogenesis17,18.
Although TAK1 has been reported to be essential for cytokine signaling and cellular homeostasis in the liver, 
its role in chronic HBV infection remains largely unknown. Our previous reports indicate that TAK1 is involved 
in the suppression of HBV replication induced by the activation of TLRs in hepatocytes11. Therefore, it is of 
interest to study the potential function of TAK1, and the underlying mechanism, in the innate immune control 
of HBV replication.
Results
Silencing of TAK1 using siRNA, or treatment with TAK1 inhibitor (5-Z-7-Oxozeaenol), enhances 
HBV replication and gene expression in cell culture. We first investigated the effects of TAK1 on HBV 
replication using loss-of function experiments. TAK1 specific (si-TAK1) or negative control (si-con) siRNAs were 
delivered into stably HBV-transfected HepG2.2.15 cells, and HBV replication and expression were evaluated. 
The silencing efficiency of si-TAK1 was confirmed by Western blot (Fig. 1A) and real-time PCR (Suppl. Fig. 1A). 
TAK1 knockdown dose dependently increased the amount of intracellular HBV replicative intermediates (HBV 
RI), HBV capsid, and HBcAg protein, as well as the titers of HBsAg and HBeAg in culture supernatants, com-
pared to controls (Fig. 1A).
Similarly, co-transfection of siTAK1 into Huh7 cells with the replication-competent HBV plasmid, pHBV1.3, 
enhanced intracellular HBV replication and HBcAg expression, as well as HBsAg and HBeAg expression 
(Suppl. Fig. 1B). Furthermore, we confirmed the effect of TAK1 knock down on HBV transcription and replica-
tion in HBV infection system by using HepG2-NTCP cells. HepG2-NTCP cells with TAK1 stably knock down 
were generated by transducing cells with sh-TAK1 lentiviral vector, while sh-con containing non-silencing short 
hairpin RNA was used as a negative control. The knockdown efficiency of sh-TAK1 was verified by Western blot 
(Supp. Fig. 1C). As expected, knock down of TAK1 led to an increased level of both HBsAg and HBeAg on day 3, 
6 and 9 post infection (Supp. Fig. 1D), which suggested that TAK1 knock down enhanced HBV replication and 
gene expression in infection system.
5Z-7-Oxozeaenol (5Z-7-Ox) is a natural resorcylic lactone of fungal origin that selectively inhibits TAK1 
kinase activity, whereas it does not significantly inhibit TAK1 expression19. Consistently, treatment of HepG2.2.15 
cells with 5Z-7-Ox had no significant effect on TAK1 expression, but led to an increase of intracellular HBV 
RI, HBV capsid, and HBcAg protein, as well as the titers of HBsAg and HBeAg in culture supernatants, in a 
dose-dependent manner (Fig. 1B). Thus, the kinase activity of TAK1 is required for TAK1-mediated inhibition of 
HBV replication and gene expression in hepatocytes.
Overexpression of TAK1 inhibits HBV replication and gene expression in cell cultures. To exam-
ine the effect of overexpression of TAK1 on HBV replication and gene expression, Huh7 cells were co-transfected 
with pHBV1.3 and either the plasmid encoding human TAK1 (HA-hTAK1) or the control vector (HA-pXJ40). As 
shown in Fig. 2A, overexpression of TAK1 significantly reduced the amount of intracellular HBV RI, HBV cap-
sid, and HBcAg protein, as well as the titers of HBsAg and HBeAg in culture supernatants, in a dose-dependent 
manner. The expression of TAK1 protein in transfected cells was confirmed by TAK1 and HA-tag Western blot 
analysis (Fig. 2A, middle panel). Consistently, overexpression of TAK1 also inhibited HBV replication and gene 
expression in HepG2 cells transfected with pHBV1.3 (Fig. 2B). However, TAK1 (HA-TAK1) did not significantly 
inhibit HBV replication when it was co-transfected into Huh7 or HepG2 cells with pCMV-HBV, in which HBV 
pgRNA transcription is under the control of the cytomegalovirus-IE promoter (Fig. 2C). This observation sug-
gests that TAK1-mediated antiviral activity against HBV was limited to HBV transcription governed by the HBV 
core promoter.
TAK1 regulates HBV core promoter activation through FXRα to suppress HBV transcription. 
Considering that the hepatocyte-specific deletion of TAK1 in mice results in spontaneous hepatocyte death and 
carcinogenesis17,18, we performed CCK-8 assay to examine whether TAK1 overexpression or inhibition influence 
cell viability. The results showed that TAK1 plasmid, siTAK1 and 5Z-7Ox had no significant effect on HepG2.2.15 
and Huh7 cell viability compared to controls (Supp. Fig. 2A,B,C). In order to verify whether TAK1-mediated 
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inhibition of HBV replication and gene expression was due to transcriptional regulation, we examined the effect 
of TAK1 on HBV RNA levels and the transcription activity of HBV promoters. Northern blot analysis showed a 
decrease of HBV transcripts in Huh7 cells under TAK1 overexpression (Fig. 3A), with core promoter (CP) and 
X promoter (XP) transcriptional activities reduced to approximately 20% and 30%, respectively (Fig. 3B). In 
contrast, knockdown of TAK1 by si-TAK1 increased HBV transcripts (Fig. 3C) and CP activity approximately 
2.5-fold, but had no significant effect on other (XP, SP1, and SP2) promoters (Fig. 3D). Since HBV core pro-
moter transcription activity is controlled by a set of liver-specific transcription factors6, we examined whether 
TAK1 affects the expression of these transcription factors. Eleven transcription factors which have previously 
been reported to bind to the HBV core promoter were selected and screened by real-time PCR. Interestingly, 
we observed that the expression of FXRα was elevated by approximately 2.0-fold after knockdown of TAK1 in 
HepG2.2.15 cells (Fig. 3E), the upregulation of FXRα by TAK1 knockdown was further verified by Western blot 
Figure 1. Silencing of TAK1 using siRNA, or treatment with TAK1 inhibitor (5-Z-7-Oxozeaenol), enhances 
HBV replication and gene expression in cell culture. (A) HepG2.2.15 cells were transfected with validated 
TAK1 siRNA or control siRNA, as indicated, and cultured for 4 days. Cell lysates and culture supernatants 
were harvested on day 4 after transfection, levels of HBV DNA replicative intermediates were determined by 
Southern blot analysis (top panel). TAK1, intracellular HBcAg expression and core particles were analyzed 
by Western blotting with β -actin as loading control (middle panel). HBsAg and HBeAg were detected in the 
culture supernatants by CMIA assay (bottom panel). (B) HepG2.2.15 cells were treated with the specific TAK1 
inhibitor, 5-Z-7-Oxozeaenol (5Z-7-Ox), at the indicated concentrations for 4 days. Cell lysates and culture 
supernatants were harvested on day 4. Levels of HBV replicative intermediates (top panel), TAK1, intracellular 
HBcAg expression, core particles (middle panel), and levels of HBsAg and HBeAg (bottom panel) were 
determined as described above. RC, relaxed circular; DL, double stranded linear; SS, single stranded.
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(Fig. 3F). Transcription activity of the FXRα promoter was also enhanced after silencing of TAK1, indicating that 
TAK1 negatively regulates FXRα expression at the level of transcription (Suppl. Fig. 2D).
TAK1 inhibition of HBV replication and gene expression requires activation of downstream 
MAPK pathways. TAK1 can be activated by multiple cytokines, and a TAK1 deletion mutant missing 
the N-terminal 22 amino acids is constitutively active20. In addition, TAK1 containing a point mutation in its 
ATP-binding domain (K63W), which abolishes its kinase activity, is unable to activate downstream signaling 
pathways20. We constructed dominant negative (DN-hTAK1) and constitutively active (CA-hTAK1) TAK1 plas-
mids as described14. Similar to wild type HA-hTAK1, transfection of CA-hTAK1 suppressed HBV replication, 
Figure 2. Overexpression of TAK1 inhibits HBV replication and gene expression in cell cultures. (A) A 
plasmid encoding pgRNA of wild-type HBV (pHBV1.3) was co-transfected into Huh7 cells with a control 
plasmid and a plasmid expressing TAK1 as indicated, and cultured for 3 days. Cells were harvested 72 h after 
transfection and the levels of HBV DNA replicative intermediates were determined by Southern blot analysis 
(top panel). HBV capsid, HBcAg, TAK1 and HA-tag protein levels were determined by Western blotting 
(middle panel; β -actin was used as a loading control), and the levels of HBsAg and HBeAg in supernatants 
were determined by CMIA. (B) HepG2 cells were transfected in the same way as Huh7 cells. HBV replicative 
intermediates and the HBV proteins HBsAg and HBeAg were determined as described above. (C) Huh7 and 
HepG2 cells were co-transfected with 1.5 μ g of the CMV-HBV plasmid and 1.5 μ g of pXJ40-HA or HA-hTAK1. 
The levels of HBV DNA replicative intermediates were determined by Southern blot. RC, relaxed circular; DL, 
double stranded linear; SS, single stranded.
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Figure 3. TAK1 regulates HBV core promoter activation through FXRα to suppress HBV transcription. 
(A) Huh7 cells were co-transfected with pHBV1.3 and HA-hTAK1 and control vector (HA-pXJ40) as 
indicated. Levels of HBV RNAs were determined by Northern blot 72 h after transfection. (B) Huh7 cells were 
co-transfected with 100 ng each of four reporter plasmids containing HBV promoters (pCP, pXP, pSP1, and 
pSP2) and 100 ng of HA-TAK1 or pXJ40-HA to analyze the effect of TAK1 overexpression on transcription 
activity from HBV promoters. For each transfection, 100 ng of pRL-TK was included as an internal control 
for transfection efficiency. Cells were harvested 48 h after transfection, and firefly and Renilla luciferase 
activities were measured; luciferase levels were normalized against those generated by the pGL3-basic control 
plasmid. (C) HepG2.2.15 cells were transfected with siRNA targeting TAK1 (si-TAK1) or control siRNA 
(si-con) as indicated. Cells were harvested 72 h after transfection and total cellular RNA were extracted and 
analyzed by Northern blot. (D) Huh7 cells were co-transfected with 100 ng of each of four reporter plasmids 
containing HBV promoters (pCP, pXP, pSP1, and pSP2) and 20 nM of si-TAK1 or negative control siRNA. For 
each transfection, 100 ng of pRL-TK was included as an internal control of transfection efficiency. Cells were 
harvested 48 h after transfection, and firefly and Renilla luciferase activities were measured and normalized 
against those produced by the pGL3-basic control plasmid. (E) HepG2.2.15 cells were transfected with si-TAK1 
or control siRNA (20 nM). The mRNA levels of associated transcription factors were determined by RT-PCR. 
(F) HepG2.2.15 cells or Huh7 cells were transfected with si-TAK1 or control siRNA (20 nM) and FXRα and 
TAK1 expression were verified by western blot.
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transcription, and gene expression in Huh7 cells. (Fig. 4A, lanes 2 and 4). In contrast, a small increase in HBV 
replication was observed by DN-hTAK1 transfection, perhaps due to its dominant-negative effect on the endog-
enous TAK1 activity (Fig. 4A, lane 3). Consistently, CA-hTAK1 also suppressed transcription from HBV core 
and X promoters (Fig. 4B). Similar to the observations in Huh7 cells, DN-hTAK1 did not affect HBV replication 
and gene expression in HepG2 cells (suppl. Fig. 3A). Consistent with the kinase inhibitor results (Fig. 1B), these 
results further confirmed that TAK1 inhibition of HBV replication depends on its kinase activation of down-
stream pathways.
To explore which signaling pathways were activated by TAK1, different types of TAK1 expression plasmids 
were delivered into Huh7 cells, which were then cultured for 12 h. Western blotting analysis of total cell lysates 
was performed to detect phosphorylated p38, JNK1/2, ERK1/2, and NF-κ B p65. The results showed that both 
HA-hTAK1 and CA-hTAK1 increased the phosphorylation of p38 and JNK1/2, and, to a lesser extent, that of 
NF-κ B p65. As expected, DN-hTAK1 had no effect on the level of phosphorylation of these proteins (Fig. 4C). 
No differences were observed in basal protein expression levels of ERK, JNK, p38, and NF-κ B p65, or phospho-
rylation of ERK1/2 in any transfections (Fig. 4C). We also confirmed that inhibition of TAK1 activity by 5Z-7-Ox 
treatment, or si-TAK1 transfection, led to a significant suppression of the phosphorylation of MAPK JNK/ERK/
p38 proteins in Huh7 cells (Suppl. Fig. 3B,C).
In addition, luciferase assays of the reporter plasmids pNF-κ B and pAP-1 confirmed that overexpression of 
HA-hTAK1 and CA-hTAK1 led to a significant increase of NF-κ B and AP-1 promoter activities in Huh7 cells; 
however, DN-TAK1 had a negligible effect on luciferase expression from these reporters (Fig. 4D). Moreover, the 
induction of AP-1 transcription activity by TAK1 was stronger than that of NF-κ B, suggesting that TAK1 may 
preferentially activate downstream MAPK p38 and JNK pathways in hepatocytes.
The MAPK-JNK pathway is involved in TAK1-mediated antiviral function. To identify which 
downstream signaling pathway is essential in the TAK1-mediated suppression of HBV replication in hepatocytes, 
inhibitors of the NF-κ B pathway and the different arms of the MAPK pathway, were used to determine whether 
they abolish the suppressive effect of TAK1 on HBV replication. The specific inhibitory effects of the different 
signaling inhibitors were validated by Western blot, as previously described21. The MAPK-JNK pathway inhibitor 
SP600125 clearly blocked the antiviral effect of TAK1 (Fig. 5A, lane 10), indicating the essential role of this path-
way in controlling of HBV replication. Of interest, the p38 pathway inhibitor, SB203580, enhanced the antiviral 
effect of TAK1 on HBV replication (Fig. 5A, lane 6), consistent with a previous publication indicating that sup-
pression of MAPK-p38 inhibits hepatitis B virus replication in human hepatoma cells22.
Furthermore, we investigated which molecules of the JNK pathway are involved in controlling HBV repli-
cation. Proteins, including JIP1, JIP2, JIP3, JIP4, KSR, POSH, MKK7, JNK1, JNK2, and JNK3, are reported to 
be members of the JNK signaling pathway23. By screening with specific siRNAs targeting these molecules in 
HepG2.2.15 and Huh7 cells, we identified that silencing of JNK3 could enhance HBV replication, compared with 
negative control siRNA (Suppl. Fig. 4A,B). In contrast, overexpression of JNK3a1 or JNK3a2 in Huh7 cells inhib-
ited HBV replication (Fig. 5B). Moreover, the inhibitory effect on HBV replication by TAK1 could be partially 
blocked by co-transfection of si-JNK3 with HA-TAK1 (Fig. 5C). Interestingly, we observed that silencing of JNK3, 
or treatment with the JNK pathway inhibitor, SP600125, could up-regulate the expression of FXRα in Huh7 and 
HepG2.2.15 cells (Fig. 5D). These results suggest that JNK3 may also regulate FXRα expression to regulate HBV 
replication.
Administration of TAK1 by hydrodynamic injection led to HBV inhibition in a mouse model 
of chronic HBV infection. To further investigate the role of TAK1 in HBV infection in vivo, we induced 
chronic HBV infection in wild-type C57BL/6 mice using hydrodynamic injection (HI) to deliver the HBV rep-
licative plasmid. pAAV-HBV1.2 plasmid (10 μ g) was injected hydrodynamically into the tail veins of 6 week-old 
male C57BL/6 mice, along with 10 μ g of either a plasmid expressing mouse TAK1 (mTAK1), or a control plasmid 
(pXJ40-flag). Serum and liver samples were collected at different time points as indicated. HBsAg levels in the 
sera of the mTAK1 plasmid injection group were significantly lower at 4 and 7 dpi than those in the pXJ40-flag 
group (p = 0.0047 and 0.0003, respectively; Fig. 6A). In addition, levels of HBeAg were significantly lower at 7 
(p = 0.0135) and 14 (p = 0.0379) dpi (Fig. 6B). Serological HBV DNA was significantly inhibited in the mTAK1 
group compared with the control group at 4 (p = 0.0002) and 7 (p = 0.0002) dpi (Fig. 6C). Consistent with 
changes in serological DNA and HBV antigens, Southern blot analysis showed that liver HBV RI was inhibited in 
the mTAK1 group, compared with the control group, at 4 and 7 dpi (Fig. 6D). By IHC staining, HBcAg expression 
and the frequency of HBcAg-positive hepatocytes were lower in the mTAK1 injection group than in controls 
(Fig. 6E). These findings suggest that TAK1 inhibits HBV replication and gene expression in vivo.
Increased TAK1 expression in the liver tissues of chronic HBV infection with hepatic inflammation. 
CHB patients in the immune active status exhibit liver inflammation over a period of months or years, as the 
immune system attempts to clear the infection, resulting in abnormal ALT levels and fluctuant viral loads24. To 
examine the role of TAK1 in chronic HBV infection, we enrolled 27 treatment-naïve CHB patients and divided 
these patients into “Inflammatory” group (n = 9) and “Non-inflammatory” group (n = 18) (Suppl. Fig. 5A). By 
analyzing the levels of TAK1 mRNA in liver biopsy samples obtained from these CHB patients, we found that 
“Inflammatory” group had significantly elevated levels of TAK1 mRNA expression in the liver, compared with 
“Non-inflammatory” group (Suppl. Fig. 5B). However, there was no significant correlation of TAK1 expression 
and HBV DNA levels, indicating that multiple factors (host and viral) are involved in shaping HBV fitness and 
immunopathogenesis. Considering the observed antiviral effect of TAK1 in hepatocytes, we speculated that the 
upregulation of TAK1 in the inflammation liver might participate in the immune control of HBV replication in 
CHB patients.
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Figure 4. TAK1 inhibition of HBV replication and gene expression requires activation of downstream 
MAPK pathways. (A) Huh7 cells were co-transfected with 1.5 μ g of pHBV1.3 and 1.5 μ g of pXJ40-HA, or 
plasmids expressing HA-hTAK1, DN-hTAK1 or CA-hTAK1. Cells were harvested 72 h after transfection. HBV 
RI, viral RNAs and HBsAg and HBeAg were determined as described above. HA-tag and β -actin (loading 
control) were examined by Western blot, 28 S/18 S rRNAs served as loading controls for Northern blot analysis. 
(B) Huh7 cells were co-transfected with 100 ng of pCP or pXP, and 100 ng of pXJ40-HA or plasmids expressing 
HA-hTAK1, DN-TAK1 or CA-TAK1. Cells were harvested 48 h after transfection and firefly and Renilla 
luciferase activities were measured and normalized against those generated by the pGL3-basic control plasmid. 
(C) Huh7 cells were transfected with 1.5 μ g of pXJ40-HA or plasmids expressing HA-hTAK1, DN-TAK1, and 
CA-TAK1. Phosphorylation and basal expression levels of p38, JNK, ERK, and NF-κ Bp 65 were analyzed by 
Western blot 12 h after transfection, using β -actin as loading control. (D) Huh7 cells were seeded in 24-well 
plates and transfected with 100 ng of the reporter plasmids pNF-κ B-luc (pNF-kB) or pAP1-luc (pAP-1) and 
100 ng of pXJ40-HA, hTAK1, DN-TAK1, or CA-TAK1. For each transfection, 100 ng of pRL-TK was included as 
an internal control of transfection efficiency. Cells were harvested 48 h after transfection and firefly and Renilla 
luciferase activities were measured and normalized against those generated by the pGL3-basic control plasmid.
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Discussion
In this study, to better define the mechanism whereby host factors restrain HBV, we investigated the impact of 
TAK1 and its downstream pathways on HBV replication and gene expression. We found that TAK1 suppresses 
HBV replication in HBV-producing cell lines, as well as in a hydrodynamic injection mouse model. Moreover, 
TAK1 exerts its antiviral effect at the level of transcription by regulation of FXRα expression, and its effects 
depended on intracellular signal transduction. We also identified JNK3, a component in the TAK1-activated 
MAPK-JNK pathway, as a potential downstream factor responsible for suppression of HBV. Therefore, we pro-
pose that TAK1 is an intrinsic host antiviral factor that restricts HBV amplification in hepatocytes.
The pathogenesis of chronic HBV infection involves complicated mechanisms related to viral persistence 
and the host immune system3. Although HBV is unable to modify host cellular gene transcription significantly, 
Figure 5. The MAPK-JNK pathway is involved in TAK1-mediated antiviral function. (A) Huh7 cells 
were co-transfected with 1.5 μ g of pHBV1.3 and 1.5 μ g of HA-hTAK1 or pXJ40-HA plasmids and, 6 h after 
transfection, cells were left untreated (lane 1, 2) or treated with 2 μ M of different inhibitors for 3 days as 
indicated. The dimethyl sulfoxide concentration in all experimental groups was 0.1%. HBV RI was analyzed 
by Southern blot 72 h after transfection. (B) Huh7 cells were co-transfected with 1.5 μ g pHBV1.3 and 1.5 μ g 
pcDNA3, or plasmids expressing JNK3a1 or JNK3a2, which were expressed for 3 days. HBV DNA replication 
was analyzed by Southern blot 72 h after transfection. Flag-tag and β -actin were examined by Western blot.  
(C) Huh7 cells were co-transfected with 1.5 μ g of pHBV1.3 and 1.5 μ g of HA-hTAK1 or pXJ40-HA plasmids, 
plus 20 nM of negative control siRNA or si-JNK3, as indicated. HBV DNA replication was analyzed by Southern 
blot 72 h after transfection. JNK3 and β -actin were examined by Western blot. (D) HepG2.2.15 or Huh7 cells 
were transfected with 20 nM of si-JNK3 or treated with 2 μ M of SP600125 for 48 h, and FXRα expression was 
determined by Western blot, with β -actin used as a loading control. *p < 0.05.
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or induce IFN-stimulated gene expression in the liver of experimentally infected chimpanzees25, approximately 
50% of HBV patients produce detectable levels of serum TNF-α , IL-6, and IL-1β within 10 days after initiation of 
viral expansion and before the peak of viremia26. These induced cytokines exhibit antiviral activity in both HBV 
Figure 6. Administration of TAK1 by hydrodynamic injection led to HBV inhibition in a mouse model of 
chronic HBV infection. Six-week old male C57BL/6 mice were co-injected with 10 μ g of pAAV-HBV1.2 and 
10 μ g of flag-mTAK1 (n = 8) or control plasmid (n = 8) by hydrodynamic injection. Serum and liver samples 
were collected at different time points. (A,B) Serological markers of HBV infection (HBsAg, HBeAg) were 
assayed at the indicated time points. (C) Serological HBV DNA was assayed at the indicated time points. Data 
are presented as log10 copies/ml. (D) Mouse liver tissues were collected from the control and TAK1 treated 
mice at 4 and 7 dpi, and HBV RI levels were determined by Southern blot. RC, relaxed circular; DL, double 
stranded linear; SS, single stranded. (E) Liver tissue sections obtained at 4 and 7 dpi were stained with anti-HBc 
antibodies (magnification, 200x, left panel). The number of HBcAg positive hepatocytes was counted, and data 
are presented as means ± SEM (right panel). *p < 0.05, **p < 0.01.
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transgenic mice and cell culture systems8,27. Of note, in response to these cytokines, TAK1 mediates the activa-
tion of downstream signaling pathways as an important adaptor protein15. Our findings clearly demonstrate that 
TAK1 suppresses HBV replication and gene expression in cell lines and a mouse model, which may explain the 
role of these cytokines in the intracellular antiviral response of hepatocytes. Further, by analyzing the levels of 
TAK1 mRNA in liver biopsy samples obtained from CHB patients, we found that inflammatory group patients 
with abnormal ALT levels had significantly elevated levels of TAK1 mRNA expression than non-inflammatory 
group (Fig. 6). Thus, we speculate that the upregulation of TAK1 might contribute to viral control in chronic HBV 
infection.
In addition to the cytokines mentioned above, TLR-mediated innate immunity also plays an important role in 
control of HBV replication28. Previously, we have determined that TLR2 or TLR4 ligands are able to inhibit HBV 
and Woodchuck hepatitis virus replication through activation of IFN-independent pathways in primary wood-
chuck hepatocytes or hepatoma cell lines11,21. Moreover, direct activation of cellular pathways through the expres-
sion of signaling adaptors also inhibited HBV replication. Guo et al. showed that the activation of the NF-κ B 
pathway by expression of TLR adaptor molecules (MyD88, TRIF, or IPS-1) in hepatoma cells suppresses HBV 
replication and transcription29. TAK1 can be activated by TLR ligands and is necessary for TLR-mediated signal 
transduction and production of antiviral cytokines15. However, we found that treatment of HepG2.2.15 cells using 
conditioned medium from cells transfected with a plasmid expressing TAK1, did not reduce HBV replication 
or gene expression (data not shown). Our observations of the antiviral function of TAK1 thus reemphasize the 
importance of the TLR signaling pathway in the control of HBV replication, and indicate that the antiviral activity 
of TAK1 against HBV may be largely dependent on intracellular factors, rather than the secreted cytokines.
To identify intracellular factors involved in TAK1-mediated antiviral effects, we first determined the 
downstream events in the NF-κ B pathway, and different arms of the MAPK pathway, mediated by TAK1 
over-expression. Using various forms of TAK1 expression plasmids, we found that TAK1 induced signal transduc-
tion was necessary for HBV inhibition. Interestingly, the P38 and JNK pathways, but not the ERK or NF-κ B path-
ways, were predominantly activated by wild type and constitutively active TAK1 in hepatocytes. Furthermore, the 
JNK pathway was apparently responsible for the suppression of HBV replication, as the JNK inhibitor, SP600125, 
and JNK3 siRNA attenuated the antiviral effects of TAK1. Based on these observations, we conclude that TAK1 
may trigger JNK pathway activation, leading to reduction of HBV replication and transcription.
Previously, both our group and Chang et al. demonstrated that suppression of phosphorylation of p38 using 
the inhibitor SB203580 could impede intracellular HBV replication11,22, while another study reported that acti-
vation of the p38 pathway could enhance HBV replication and gene expression30. As the inhibition of the p38 
pathway by SB203580 has been shown to enhance TAK1-induced activation of the JNK pathway31, it is likely that 
TAK1 might preferentially activate the JNK pathway to override the positive effect of the p38 pathway on HBV 
replication. By screening of siRNAs, we identified JNK3 as a downstream transmitter of TAK1-mediated antiviral 
signaling. These new findings suggest that the components of the JNK pathway should be analyzed further to 
investigate their role(s) in control of HBV replication.
The data presented herein further elucidate the mechanisms involved in HBV transcription regulation. There 
are many liver-enriched transcription factors, especially nuclear receptors, which can bind to HBV promoters to 
regulate HBV transcription and to facilitate its replication6. Previously, the cytokine IL-6, which activates TAK1, 
was found to inhibit HBV replication at the level of transcription and down-regulate expression of HNF1α and 
HNF4α 12. To determine whether the observed reduction of HBV RNAs upon overexpression of TAK1 is via 
the mechanism of transcriptional regulation, we determined that HBV pgRNA can be efficiently reduced by 
TAK1 in an HBV core promoter-dependent manner. We found that TAK1 knockdown, as well as JNK pathway 
inhibition, could upregulate the mRNA and protein expression of FXRα , a transcription factor that binds to two 
motifs within the HBV enhancer II and core promoter regions to enhance HBV transcription and replication32,33. 
However, due to the limitations of real-time RT-PCR screening, there may be other undefined transcription fac-
tors regulated by TAK1, as we observed a discrepancy in the results of TAK1 over-expression and knockdown on 
X promoter activity. Nevertheless, our data suggest that the activation of JNK pathway by TAK1 leads to downreg-
ulation of transcription factor FXRα and in turn results in HBV suppression. Although FXRα activation by bile 
acids antagonizes the JNK signaling pathway in liver carcinogenesis34, the mechanism of JNK pathway regulation 
of FXRα requires further investigation.
Taken together, our results provide insights into a new role for the TAK1/JNK/FXRα cascade in regulating 
HBV replication and gene expression. The TAK1-mediated antiviral effect can be induced by cytokines or activa-
tion of TLRs, which results in non-cytopathic inhibition of HBV replication in hepatocytes, an important process 
in immune control of HBV infection. Non-cytopathic inhibition of viral gene expression is an attractive means of 
therapeutic control for infections, and for HBV in particular. Future advances in the understanding of intracellu-
lar anti-HBV host factors will assist in the development of strategies to find a cure for HBV infection.
Materials and Methods
Reagents. The TAK1 inhibitor 5Z-7-Oxozeaenol and the NF-κ B pathway inhibitor BAY11–7082 were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). SP600125 (JNK pathway inhibitor), SB203580 (p38 pathway 
inhibitor), and PD98059 (ERK pathway inhibitor) were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Pre-designed small interfering RNAs (siRNAs) were bought from Qiagen (Hilden, Germany) and 
their sequences are listed in Supplementary Table 1.
Plasmids and vector construction. The HBV (genotype D, subtype ayw) replication-competent plas-
mids, pHBV1.3 and pCMV-HBV, in which the transcription of viral pgRNA is governed by an authentic HBV 
core promoter and a cytomegalovirus-IE promoter, respectively, have been described previously35. To construct 
the HA-tagged human TAK1 (HA-hTAK1) and flag-tagged murine TAK1 (flag-mTAK1) vectors, the full-length 
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coding regions for hTAK1 and mTAK1 were PCR amplified and cloned into empty pXJ40-HA or pXJ40-flag 
vectors (Addgene, Cambridge, MA, USA). Plasmids containing constitutively active hTAK1 (CA-hTAK1), 
which lacks the first 66 nucleotides, cloned into pXJ40-HA and dominant negative hTAK1 (DN-hTAK1), with a 
point mutation of lysine-63 in the ATP-binding site, were constructed according to a previous report20, using a 
QuickChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA). pcDNA3-flag-JNK3a1 (13758#) 
and pcDNA3-flag-JNK3a2 (13759#) were purchased from Addgene (Cambridge, MA, USA). Luciferase reporter 
vectors pNF-κ B-luc, pAP-1-luc, and pRL-TK were purchased from Clontech (Mountain View, CA, USA). The 
pGL3-basic derived luciferase reporter vectors, pSP1, pSP2, pCP, pXP, and pFXRα were previously generated and 
described33. All constructed vectors were subjected to DNA sequencing to verify that the nucleotide sequences 
were correct. The primers (Invitrogen, Shanghai, China) used for cloning are listed in Supplementary Table 2.
Cell culture and transfection. Human hepatoma cell lines, HepG2, Huh7 and HepG2-NTCP cells sta-
bly expressing human NTCP (kindly provided by Prof. Wenhui Li)4 were grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μ g/ml streptomycin, and main-
tained at 37 °C in 5% CO2. HepG2.2.15 cells with integrated dimers of the HBV genome (GenBank Accession 
number U95551) were cultured with 500 μ g/ml of G418 (Sigma-Aldrich). Plasmids or siRNAs were transfected 
into cells at the indicated concentrations using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s instructions.
Lentivirus transduction and HBV infection. The GV248 lentiviral vector sh-TAK1 containing short 
hairpin RNA targeting sequence (5′ - GTGTGTCTTGTGATGGAAT-3′ ) and the negative control lentiviral vector 
sh-Con were obtained from Genechem Company Ltd (Shanghai, China) and were used to knock down TAK1 
expression. To generate clones stably knock down TAK1, the HepG2-NTCP cells first were infected at a multiplic-
ity of infection of 20 with sh-TAK1 or sh-Con. Stable clones were selected after 2 weeks using puromycin and the 
expression level of TAK1 was determined by Western blot. HBV infection of HepG2-NTCP cells was performed 
according to Prof. Wenhui Li’s protocol4. Briefly, HepG2-NTCP cells were seeded in 6-well plates and infected 
with HBV at 100 genome equivalent (GEq)/cell in the present of 4% polyethylene glycol (PEG 8000; Sigma) for 
16 h, and then rinsed three times with phosphate-buffered saline and maintained in the maintenance medium 
containing 2.5% dimethyl sulfoxide. The supernatant samples were collected at 3, 6 and 9 days post infection and 
HBsAg and HBeAg were assessed.
Analysis of HBV replication and gene expression. HBV replicative intermediates (HBV RI) from 
intracellular core particles, and total cellular RNA were extracted from cells or liver tissue as described pre-
viously33. Samples were electrophoresed into agarose gels and blotted onto Hybond-XL membranes (GE 
Healthcare, Marlborough, MA, USA). Then, the membranes were probed with a DIG-labeled specific full-length 
HBV riboprobe, generated using the PCR DIG Probe Synthesis Kit (Roche, Basel, Switzerland), and visualized 
with CDP-Star using an ImageQuant LAS 2000 mini system (GE Healthcare). The densitometry of nucleic acid 
bands were analyzed by Image-Pro Plus software (Media Cybernetics Inc, Silver Spring, MD) and the values 
were presented below each of the blots as the percentage of control samples. The levels of HBsAg and HBeAg in 
culture supernatants were determined using the Architect system and HBsAg and HBeAg CMIA kits (Abbott 
Laboratories, North Chicago, IL, USA) according to the manufacturer’s instructions.
Western blot analysis. Protein samples were subjected to SDS-PAGE gel electrophoresis and blotted with 
primary antibodies recognizing HA-tag, TAK1, β -actin, JNK1/2/3, ERK1/2, p38, NF-κ B p65, phospho-JNK1/2, 
phospho-ERK1/2, phospho-p38, phospho-NF-κ B (p65) (Cell Signaling Technology), FXRα (R&D Systems, 
Minneapolis, MN, USA), and HBcAg (Abcam, Cambridge, MA, USA). Protein bands were visualized using ECL 
Plus western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK) and an ImageQuant 
LAS 2000 mini system, as previously described11.
Quantitative realtime-PCR assay. DNase I-treated total cellular RNA was reverse-transcribed into cDNA 
using a QuantiTect Reverse Transcription Kit (Qiagen). The expression of different cellular genes was determined 
by quantification of specific mRNAs using commercial QuantiTect Primer Assays (Qiagen; primer sequences are 
not available). Real-time PCR was performed using a SYBR Green Master kit (Roche) in the Roche LightCycler 
480 system. For each sample, RT-PCR was performed in triplicate. The expression levels of each gene are pre-
sented as values normalized against 106 β -actin transcripts.
Luciferase reporter assay. Approximately 2 × 105 HepG2.2.15 or Huh7 cells were seeded in 24-well plates 
one day before transfection. siRNA (20 nM) or vectors expressing hTAK1 (100 ng) were co-transfected with var-
ious firefly reporters (100 ng), and a Renilla luciferase reporter pRL-TK (100 ng) was added to each transfection 
to correct for transfection efficiency. After 48 h, cells were washed with PBS and resuspended in lysis buffer from 
the DualGlo Luciferase Assay system (Promega, Madison, WI, USA), followed by detection of luciferase activity 
in a luminometer (PerkinElmer, Norwalk, CT, USA). Relative firefly luciferase activities were normalized to those 
of Renilla luciferase activities.
Cell viability analysis. HepG2.2.15 cells transfected with si-TAK1 or treated with 5Z-7-Oxozeaenol and 
Huh7 cells transfected with HA-hTAK1 plasmid were seeded at a density of 2 × 103 cells per well in 96-well plates, 
and then the viability of the cells was assessed from 4 replicates at 3 or 4 days post transfection using the Cell 
Counting Kit-8 (Dojindo, Kumamoto, Japan).
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Microarray analysis of intrahepatic gene expression in CHB patients. A total of 27 treatment-naïve 
CHB patients were enrolled in this study and liver biopsies were collected. All patients were recruited with 
informed written consent. The study was approved by the Institutional Ethics Committee for human studies at 
Huashan Hospital, Fudan University. All clinical investigations have been conducted according to the principles 
expressed in the Declaration of Helsinki. Total mRNA was isolated from liver specimens and the gene expression 
profiling was performed by using Affymetrix Human U133 Plus 2 arrays at Ebioservice, Inc (Shanghai, China). 
Microarray data were analyzed using GeneSpring GX 10 (Agilent). The complete microarray dataset will be pub-
lished separately. In this study, the TAK1 gene expression data were expressed as log2 values with mean ± SD, a 
p-value < 0.05 (t-test) is considered significant.
Animal experiments. C57BL/6 mice (male, 5–6 weeks old) were treated according to the guidelines of the 
National Institutes of Health for Animal Care and Use. The animal experimental protocol was approved by the 
Nanfang hospital animal ethic committee. Hydrodynamic injection was carried out as described previously36. 
Briefly, pAAV-HBV1.2 plasmid (10 μ g; kindly provided by Professor Pei-Jer Chen, National Taiwan University), 
together with 10 μ g of flag-mTAK1 or control plasmid (pXJ40-flag), were co-injected into the tail vein of mice in 
a volume of saline equivalent to 10% of the body mass of the mouse. The total volume was delivered in 5–8 sec-
onds. Mice negative for HBsAg 1 day post injection (dpi) were excluded from the experiments. Eight mice were 
included per group. Serum samples were collected from mice at the indicated time points for HBsAg, HBeAg, 
and HBV DNA testing. Liver tissue samples were also collected and HBV replication was examined by Southern 
blot. Immunohistochemistry (IHC) staining were performed on formalin-fixed and paraffin-embedded 4 μ M liver 
tissue sections. Sections were incubated overnight at 4 °C with appropriate concentrations of rabbit anti-HBc, and 
then incubated with the Dako Chemate Envision Kit (Dako, Shanghai, China). The reaction was visualized using 
CheMate 3–3′ -diaminobenzadine plus chromogen, and the number of HBc-positive cells in the liver sections was 
independently counted by two blinded observers based on four high-power microscopic fields (400× ).
Statistical analyses. Statistical analyses were carried out using GraphPad Prism 5.0 software (San Diego, 
CA, USA). Analysis of variance with Student’s t-test was used to determine significant differences in multiple 
comparisons. The Mann–Whitney U test was used for two-group comparisons. P values < 0.05 were considered 
statistically significant. Representative data from a series of at least three experiments are shown. Data are pre-
sented as means ± standard error of the mean (SEM).
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